These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25247342)

  • 1. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy.
    Sudarski S; Shi J; Schmid-Bindert G; Manegold C; Pilz LR; Zhou C; Schoenberg SO; Henzler T
    J Thorac Oncol; 2015 Jan; 10(1):164-71. PubMed ID: 25247342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic volume perfusion CT in patients with lung cancer: baseline perfusion characteristics of different histological subtypes.
    Shi J; Schmid-Bindert G; Fink C; Sudarski S; Apfaltrer P; Pilz LR; Liu B; Haberland U; Klotz E; Zhou C; Schoenberg SO; Henzler T
    Eur J Radiol; 2013 Dec; 82(12):e894-900. PubMed ID: 24094644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.
    Knollmann FD; Kumthekar R; Fetzer D; Socinski MA
    Clin Lung Cancer; 2014 Mar; 15(2):103-9. PubMed ID: 24361250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
    Fraioli F; Anzidei M; Zaccagna F; Mennini ML; Serra G; Gori B; Longo F; Catalano C; Passariello R
    Radiology; 2011 May; 259(2):574-82. PubMed ID: 21357523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.
    Toffart AC; Moro-Sibilot D; Couraud S; Merle P; Perol M; Girard N; Souquet PJ; Mastroianni B; Ferretti GR; Romand P; Chatellain P; Vesin A; Brambilla E; Brambilla C; Timsit JF
    BMC Cancer; 2014 Dec; 14():989. PubMed ID: 25527907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
    Lau LF; Williams DS; Lee ST; Scott AM; Christophi C; Muralidharan V
    Ann Surg Oncol; 2014 Jul; 21(7):2420-8. PubMed ID: 24595797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
    Zhou T; Zheng L; Hu Z; Zhang Y; Fang W; Zhao Y; Ge J; Zhao H; Zhang L
    Sci Rep; 2015 Jan; 5():7683. PubMed ID: 25567662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC).
    Trinidad López C; De La Fuente Aguado J; Oca Pernas R; Delgado Sánchez-Gracián C; Santos Armentia E; Vaamonde Liste A; Prada González R; Souto Bayarri M
    Eur Radiol Exp; 2019 Jun; 3(1):23. PubMed ID: 31197486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.
    Hayes SA; Pietanza MC; O'Driscoll D; Zheng J; Moskowitz CS; Kris MG; Ginsberg MS
    Eur J Radiol; 2016 Mar; 85(3):524-33. PubMed ID: 26860663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy.
    Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Seki S; Sugihara N; Sugimura K
    Eur J Radiol; 2016 Jan; 85(1):176-186. PubMed ID: 26724663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.